Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Cisplatin + Gem/Nab-Paclitaxel for Pancreatic Cancer with Peritoneal Metastasis
NCT04707118Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cisplatin in pancreatic adenocarcinoma (PDAC), peritoneal metastasis (PM) and malignant ascites, sponsored by Fudan University. Status: unknown.
02
Drugs
cisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)peritoneal metastasis (PM)malignant ascites
Beyond the preview
Go deeper on NCT04707118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707118.